Journal profile · Immunology and Microbiology-Immunology
Journal of Inflammation Research
ISSN 1178-7031 · Dove Medical Press · NEW ZEALAND
Journal of Inflammation Research: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.62; JCR Q2 (journal website); fully open access; APC about USD 4,320; median 89 days to acceptance (151 articles, last 24 months); acceptance rate 8% (journal website); 1,172 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Inflammation Research is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory Biomarkers in Disease Prognosis, Ferroptosis and cancer prognosis and Inflammasome and immune disorders, together about 27.9% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Ning Quan The Journal of Inflammation Research is an international, peer-reviewed, open access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation. Specific topics covered by the journal include: acute/chronic inflammation mediators of inflammation cellular processes molecular mechanisms neuroimmune mechanisms pharmacology and novel anti-inflammatory drugs clinical conditions involving inflammation The journal welcomes the following article types on all aspects of inflammation unless otherwise stated below. The journal does not consider case reports except in circumstances where they make a valuable contribution to the literature. Protocols of prospective studies need to be accompanied by detailed and original video demonstrations of the proposed research. Bibliometric studies are welcome but must add significantly to the body of knowledge about inflammation research, and meta-analyses are not considered for publication. When considering submission of a paper utilizing publicly available data (e.g. SEER/GWAS/TCGA/GEO/Vigibase etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria. Inflammatory index submissions (including Systemic Immune-Inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI)) require a multicentre cohort or a separate independent validation cohort to confirm the reproducibility of the index's predictive ability. Studies using natural product extracts/decoctions will only be considered if the active compound(s) has been adequately identified and validated. While it is often not possible to identify the “one and only active compound” from an extract or decoction, efforts should be made to provide key insights into the active ingredient(s). Authors should consider and discuss the possibility that several active compounds exhibit a synergistic effect and, thus, the mixture is more than the sum of the effects of its purified ingredients. The journal welcomes submissions to the following sections: Autoimmunity and Inflammation Cardiovascular Inflammation Dermatological Inflammation Diabetes and Inflammation Gastrointestinal Inflammation Liver and Gall Bladder I
From the journal's Aims & Scope
Research area (LetPub): Immunology and Microbiology-Immunology
Editor-in-chief Ning QuanPublisher website
Editorial board by country: 40 in mainland China (about 25%); most named Mainland China 40, United States 37, Türkiye 9, India 8, United Kingdom 7 (161 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory Biomarkers in Disease PrognosisMedicine12.3%
- Ferroptosis and cancer prognosisMedicine8.1%
- Inflammasome and immune disordersBiochemistry, Genetics and Molecular Biology7.5%
- Sepsis Diagnosis and TreatmentMedicine5.3%
- Immune Response and InflammationImmunology and Microbiology5.1%
- Immune cells in cancerImmunology and Microbiology5%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine4.8%
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.62LetPub ·
- Impact factor (publisher) 2025
- 5.1Publisher website ·
- 5-year impact factor (publisher)
- 5.6Publisher website ·
- CiteScore 2026-06
- 5.6LetPub ·
- CiteScore (publisher) 2025
- 1.03Publisher website ·
- SJR 2026-06
- 1.17LetPub ·
- SNIP 2026-06
- 1.03LetPub ·
- h-index
- 84OpenAlex ·
- i10-index
- 1,585OpenAlex ·
- 2-year mean citedness
- 4.51OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 99.24%LetPub ·
Volume
- Articles per year
- 1,137LetPub ·
- Downloads per year (publisher)
- 356,552Publisher website ·
Articles by year OpenAlex count · 4,467 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 650 | 650 | 233 |
| 2025 | 1,172 | 1,172 | 4,899 |
| 2024 | 803 | 803 | 6,717 |
| 2023 | 460 | 460 | 7,190 |
| 2022 | 493 | 493 | 10,055 |
| 2021 | 543 | 543 | 14,580 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
89 daysMedian, submission to acceptance · P25–P75 63 days – 115 days
- Acceptance to online
- median 21 days (151 articles)
- Submission to online
- median 115 days
- Sample
- 151 articles with submission and acceptance dates (2,141 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 8%Publisher website ·
- Desk decision
- 35 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- NEW ZEALAND
- Language
- English
- ISSN
- 1178-7031
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Inflammation Research
What CAS zone is Journal of Inflammation Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Inflammation Research is in Zone 3 of Medicine, and in Zone 3 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Inflammation Research?
The latest impact factor listed by LetPub is 4.62; CiteScore 5.6, h-index 84.
How long does peer review take at Journal of Inflammation Research?
Based on the dates recorded on 151 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 89 days (interquartile range 63–115 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 8%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Journal of Inflammation Research in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Journal of Inflammation Research based?
Of the 161 board members whose country the journal's board page names, 40 (about 25%) are in mainland China; the countries named most often are Mainland China (40), United States (37) and Türkiye (9). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Inflammation Research?
According to LetPub and DOAJ records, Journal of Inflammation Research is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PubMed; that list has not been checked against each database.
Is Journal of Inflammation Research open access, and what is the APC?
Journal of Inflammation Research is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .